Iluvien is owned by Alimera Sciences Inc.
Iluvien contains Fluocinolone Acetonide.
Iluvien has a total of 1 drug patent out of which 0 drug patents have expired.
Iluvien was authorised for market use on 26 September, 2014.
Iluvien is available in implant;intravitreal dosage forms.
The generics of Iluvien are possible to be released after 12 August, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8871241||ALIMERA SCIENCES INC||Injectable sustained release delivery devices|| |
(4 years from now)
Market Authorisation Date: 26 September, 2014
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic